Related Experiment Videos
Subacute sclerosing panencephalitis aggravated during the intraventricular interferon administration therapy
H Hattori1, R Murata, O Matsuoka
1Department of Pediatrics, Osaka City University Medical School, Japan.
Osaka City Medical Journal
|July 1, 1995
Summary
Intraventricular interferon-alpha treatment in a patient with advanced Jabbour stage III disease showed no benefit and may have contributed to neurological deterioration. Autopsy revealed viral presence and inflammatory changes in the brain.
Area of Science:
- Neuroimmunology
- Virology
- Neurology
Background:
- Interferon-alpha (IFN-α) is a cytokine used in treating various conditions.
- Intraventricular administration of IFN-α via an Ommaya reservoir is a potential route for central nervous system delivery.
- Jabbour staging is used to classify the severity of certain neurological diseases.
Observation:
- A 25-year-old female patient with Jabbour stage III disease received intraventricular human lymphoblastoid interferon-alpha.
- Treatment involved escalating doses over 42 days, totaling 33,550,000 IU.
- The patient's neurological disability index score increased from 56.3% to 75% post-treatment.
Findings:
- Autopsy revealed perivascular lymphocyte infiltration, diffuse gliosis, and demyelination in the cerebrum and brain stem.
- The causative virus was isolated from the frontal lobes.
- The patient's condition worsened during and after interferon treatment, suggesting a potential negative impact.
Implications:
- Intraventricular interferon-alpha may not be effective and could potentially worsen neurological conditions.
- Further research is needed to understand the risks and benefits of direct CNS interferon administration.
- Autopsy findings highlight the importance of investigating viral persistence and inflammatory responses in treatment-refractory neurological diseases.